IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 16850 
Small font sizeDefault font sizeIncrease font size
Navigate Here
Resource Links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »  Article in PDF (210 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)

In This Article
 »  Abstract
 » Introduction
 » Case Report
 » Discussion
 »  References

 Article Access Statistics
    PDF Downloaded120    
    Comments [Add]    
    Cited by others 7    

Recommend this journal


 Table of Contents    
Year : 2014  |  Volume : 46  |  Issue : 6  |  Page : 655-656

A case of etizolam dependence

Department of Psychiatry, Institute of Human Behaviour and Allied Sciences, Dilshad Garden, New Delhi, India

Date of Submission17-Jan-2014
Date of Decision15-Mar-2014
Date of Acceptance13-Oct-2014
Date of Web Publication18-Nov-2014

Correspondence Address:
Bhavuk Garg
Department of Psychiatry, Institute of Human Behaviour and Allied Sciences, Dilshad Garden, New Delhi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0253-7613.144943

Rights and Permissions

 » Abstract 

Etizolam is a thienodiazepine anxiolytic which is said to have lower dependence potential than other benzodiazepines. We report a case of etizolam dependence in a young male with social anxiety disorder and moderate depression. This case report highlights the fact that the same caution be exercised while prescribing etizolam with respect to its potential to cause dependence as with any other benzodiazepine.

Keywords: Addiction, dependence, etizolam, thienodiazepine

How to cite this article:
Gupta S, Garg B. A case of etizolam dependence . Indian J Pharmacol 2014;46:655-6

How to cite this URL:
Gupta S, Garg B. A case of etizolam dependence . Indian J Pharmacol [serial online] 2014 [cited 2023 Sep 26];46:655-6. Available from: https://www.ijp-online.com/text.asp?2014/46/6/655/144943

 » Introduction Top

The dependence and abuse potential of benzodiazepines is well recognized. [1] This has resulted in the search for novel anxiolytics devoid of such potential. [1] Etizolam is a thienodiazepine anxiolytic and is said to have low tolerance and dependence liability than benzodiazepines. [2] We report a case of etizolam dependence in a young male with Social Anxiety disorder to highlight the abuse and dependence potential of etizolam.

 » Case Report Top

We present a case of 23-year-old male who presented to the outpatient department with 3 years history of feeling anxious in social situations, feeling scrutinized and focus of attention in social situations and marked avoidance behavior. For past few months the patient also had pervasive sadness of mood, lack of interest, ideas of hopelessness and worthlessness. The patient was diagnosed as Social Anxiety disorder with Moderate Depressive episode. The patient was earlier on treatment with paroxetine up to 12.5 mg, escitalopram 10 mg and sertraline up to 50 mg/day before coming in our contact. The patient was also taking etizolam up to 2.5 mg/day.

There was a history of progressive increase in dose of etizolam taken by the patient. Initially, he was prescribed etizolam at dose of 0.25 mg/day. Initially, he would take on S.O.S. basis when he would face any social situation. Gradually, he started taking etizolam regularly, and his intake increased to 2.5 mg/day over a period of 1 month. The patient would have palpitations, tremulousness, impaired sleep, would feel agitated on taking lower dose of etizolam resembling the characteristic benzodiazepine withdrawal symptoms. He would also have craving for etizolam. He continued to self-medicate himself with etizolam even after the physician had stopped prescribing the same. Hence, the patient was found to have tolerance and compulsion to take the substance and experienced withdrawal symptoms for etizolam and thus fulfilled the criteria for dependence syndrome as given by the International Classification of Diseases-10 (ICD-10) Classification of Mental and Behavioral Disorders. [3] The patient was prescribed paroxetine up to 25 mg/day with clonazepam 3 mg/day. The patient showed marked improvement in depression and social anxiety but continued to take etizolam. He continued his etizolam intake despite being aware that etizolam might be harmful to him and is not to be taken on long term basis. Impression diagnosis of etizolam dependence was thus made.

 » Discussion Top

Although a thienodiazepine, etizolam is clinically regarded as a benzodiazepine because of its mode of action via benzodiazepine receptor. [4] The potency and efficacy of etizolam for allosteric potentiation of γ-Aminobutyric acid evoked Cl current mediated by recombinant α1 β2 γ2S receptors is lower than those of classical benzodiazepines which has been proposed as a reason for a reduced liability of etizolam for the development of tolerance and dependence. [2] The claim of low dependence potential of etizolam has led to it being prescribed liberally in the markets where it is available for a long time, like Japan. [4] This myth is being realized now after it has become the most frequently prescribed benzodiazepine there. [5] Perhaps, this is the reason for its nonavailability in developed markets of United States of America and Europe. [6] It was approved for use in India on October 29, 2007 and perhaps because of late entry, remains one of the least used benzodiazepine in India. [6],[7]

Etizolam has been occasionally associated with skin lesions and blepharospasm. [8],[9] However, the literature about its abuse and dependence potential is sparse. The rapid relief of anxiety by ultra-short-action and feeling of anxiety after the action wears off may lead to dependence by both positive and negative behavioral reinforcement.

The case described in this article developed dependence on etizolam after experiencing relief in his anxiety symptoms with its therapeutic use. Five (a, b, c, d, and f) out of six criteria for establishing dependence syndrome (F13.2) as per ICD-10, against a diagnostic threshold of three were present in this case in context of etizolam use. Hence, a case of etizolam dependence is established beyond doubt. Paroxetine has proven efficacy for social anxiety disorder, depressive episode and for tapering benzodiazepine use [10] and successfully resulted in remission of former two conditions in this patient. However, the patient was finding it difficult to taper etizolam use and dropped out of follow-up.

This case report highlights the fact that the same caution be applied while prescribing etizolam with respect to dependence potential as for any other benzodiazepine. In the case of development of dependence, treatment of the primary disorder, substitution with longer-acting benzodiazepines, Selective Serotonin Reuptake Inhibitors and psychotherapy are various options that can be exercised.

 » References Top

Leonard BE. New developments in the pharmacological treatment of anxiety. Hum Psychopharmacol Clin Exp 1999;14:S52-9.  Back to cited text no. 1
Sanna E, Busonero F, Talani G, Mostallino MC, Mura ML, Pisu MG, et al. Low tolerance and dependence liabilities of etizolam: Molecular, functional, and pharmacological correlates. Eur J Pharmacol 2005;519:31-42.  Back to cited text no. 2
Sartorius N. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 2004.  Back to cited text no. 3
Toda K. Inclusion of thienodiazepines in prescription rate of anxiolytics. Psychiatry Clin Neurosci 2009;63:430.  Back to cited text no. 4
Shimane T, Matsumoto T, Wada K. Prevention of overlapping prescriptions of psychotropic drugs by community pharmacists. Nihon Arukoru Yakubutsu Igakkai Zasshi 2012;47:202-10.  Back to cited text no. 5
Kataria BC, Mehta DS, Chhaiya SB. Approval of new nervous system drugs in India compared with the US and EU. Int J Pharm Pharm Sci 2012;4:705-9.  Back to cited text no. 6
Grover S, Avasth A, Kalita K, Dalal PK, Rao GP, Chadda RK, et al. IPS multicentric study: Antidepressant prescription patterns. Indian J Psychiatry 2013;55:41-5.  Back to cited text no. 7
[PUBMED]  Medknow Journal  
Kuroda K, Yabunami H, Hisanaga Y. Etizolam-induced superficial erythema annulare centrifugum. Clin Exp Dermatol 2002;27:34-6.  Back to cited text no. 8
Wakakura M, Tsubouchi T, Inouye J. Etizolam and benzodiazepine induced blepharospasm. J Neurol Neurosurg Psychiatry 2004;75:506-7.  Back to cited text no. 9
Nakao M, Takeuchi T, Nomura K, Teramoto T, Yano E. Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic. Psychiatry Clin Neurosci 2006;60:605-10.  Back to cited text no. 10

This article has been cited by
1 Deprescribing clonazepam in primary care older patients: a feasibility study
Luanna Gabriella Resende da Silva, Athos Wellington da Silva Pinto, Warlen Eduardo de Queiroz, Cleiton Cláudio Coelho, Carine Raquel Blatt, Marcio Galvão Oliveira, Ana Cristina de Lima Pimentel, Monique Elseviers, André Oliveira Baldoni
International Journal of Clinical Pharmacy. 2022;
[Pubmed] | [DOI]
2 Toxicity of designer benzodiazepines: a case of etizolam and cocaine intoxication
Guillaume Drevin, Marie Briet, Severine Ferec, Chadi Abbara
Forensic Science International. 2022; : 111324
[Pubmed] | [DOI]
3 Etizolam and Its Major Metabolites: A Short Review
Abdul Aziz Al Bahri, Hilary J Hamnett
Journal of Analytical Toxicology. 2022;
[Pubmed] | [DOI]
4 Synthesis of trans N-Substituted Pyrrolidine Derivatives Bearing 1,2,4- triazole Ring
Tangella Nagendra Prasad, Yeruva Pavankumar Reddy, Poorna Chandrasekhar Settipalli, Vadiga Shanthi Kumar, Eeda Koti Reddy, Shaik Firoj Basha, Shaik Anwar
Current Organic Synthesis. 2022; 19(5): 578
[Pubmed] | [DOI]
5 Designer Benzodiazepines: A Review of Toxicology and Public Health Risks
Pietro Brunetti, Raffaele Giorgetti, Adriano Tagliabracci, Marilyn Huestis, Francesco Busardò
Pharmaceuticals. 2021; 14(6): 560
[Pubmed] | [DOI]
6 A Case Series of Etizolam in Opioid-Related Deaths
Jirair Gevorkyan, Juliet Kinyua, Sue Pearring, Luke N Rodda
Journal of Analytical Toxicology. 2021; 45(7): e4
[Pubmed] | [DOI]
7 Etizolam: A rapid review on pharmacology, non-medical use and harms
Suzanne Nielsen, Andrew McAuley
Drug and Alcohol Review. 2020; 39(4): 330
[Pubmed] | [DOI]


Print this article  Email this article


Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow